Key benefits Why people compare it 1 70% increase in collagen thickness in double-blind clinical trials at 3% concentration 2 Visible reduction in fine lines and improved skin density within 12 weeks 3 40% improvement in skin elasticity with enhanced firmness and hydration 4 No irritation, purging, or photosensitivity - superior tolerability to retinoids 5 Stimulates collagen I, III, and V synthesis plus decorin and glycosaminoglycans 6 Modulates over 4,000 genes including anti-inflammatory and antioxidant pathways 7 Phospholipid delivery system for enhanced dermal penetration and stability 8 Accelerates wound healing and reduces scar tissue formation in research models Deep research About GHK-Cu Topical Serum GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a naturally occurring copper-binding tripeptide with the amino acid sequence Gly-His-Lys bound to a Cu2+ ion

D., Cai, X., Ma, C., Wang, Y., Dai, A., Zhou, Y., Sun, W., Zhao, F., Zhao, S., Jiang, H., Jiang, Y., Yang, D., Eric Xu, H., Wang, M
Make An Appointment Feel free to reach out to us to schedule an appointment either through our reception desk or by utilizing our convenient online booking system through Hotdoc
Medications and peptides offered at Gameday Canada follow Canadian prescribing rules and are dispensed only when medically appropriate
Key Characteristics: Peptide Classification : Synthetic pentadecapeptide Sequence : GEPPPGKPADDAGLV (a partial sequence of human BPC) Bioactive Functions : Pro-angiogenic, anti-inflammatory, anti-fibrotic Stability : Highly stable in gastric juice (rare for peptides) Origin : Derived from a protein found in the stomachs protective lining Unlike most therapeutic peptides, BPC-157 is active both subcutaneously and orally , and does not require injection to achieve systemic effectsthough injections near the injury site offer superior localized outcomes
the clinical relevance of this finding in humans is unknown, and in UK and EU prescribing information this is noted as a precaution rather than a formal contraindication but individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should discuss this with their doctor